News >

FDA Grants Priority Review to Pembrolizumab for Relapsed/Refractory PMBCL

Jason Harris
Published: Monday, Dec 11, 2017

Pier Luigi Zinzani, MD, PhD

Pier Luigi Zinzani, MD, PhD
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as a treatment for adult and pediatric patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL).

Merck, the manufacturer of pembrolizumab, issued a press release announcing the agency's decision on December 11, 2017. The FDA reviewed the sBLA based on results from a cohort of the phase II KEYNOTE-170 trial evaluating the anti–PD-1 agent in 29 patients with PMBCL. The findings were first presented at the 14th International Conference on Malignant Lymphoma and updated data were recently presented at the 2017 ASH Annual Meeting.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x